Learning Objectives:

       1.  Discussion of cardiovascular disease risks

       2.  The use of GLP-1RA: Semaglutide for obesity patients with cardiovascular disease risk without diabetes

Session date: 
11/17/2023 - 7:30am to 8:30am CST
Add to calendar: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Dr. Mashaal Ikram